What question did this study set out to answer?

This analysis aims to evaluate the incidence of misdiagnosis in myxoid/round cell liposarcoma and assess the role of NY-ESO-1 testing.

Myxoid/round cell liposarcoma misdiagnosis incidence, etiology, and importance of NY-ESO-1 testing: Retrospective analysis of the Tempus database.

View Full Paper

Ask AI

Bookmark

Authors

Retrospective analysis identifies misdiagnosis rates in liposarcoma, emphasizing NY-ESO-1's role in treatment decision-making.

This analysis aims to evaluate the incidence of misdiagnosis in myxoid/round cell liposarcoma and assess the role of NY-ESO-1 testing.
Conducted a retrospective analysis using the Tempus RNA database for DDIT3 translocations and NY-ESO-1 expression in MRCLS.
Identified 101 patients with MRCLS; 74 patients had sufficient Next Generation Sequencing data for analysis.
Normalized RNA gene expression values using transcripts-per-million (TPM) converted to log2(TPM+1).
Detected DDIT3 fusion in 65/74 (88%) MRCLS cases, with 60 being DDIT3-FUS and 5 DDIT3-EWSR1.
Found a 12% misdiagnosis rate for MRCLS with WD/DD LPS misidentified as MRCLS.
All MRCLS samples with confirmed DDIT3 translocation were predicted to express NY-ESO-1, supporting its diagnostic utility.

Nathenson et al. (2026) studied this question.

View Full Paper

Ask AI

Bookmark